Home Tags BPDCN

Tag: BPDCN

IMGN632 Receives Breakthrough Therapy Designation in Relapsed or Refractory Blastic Plasmacytoid...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632, a novel CD123-targeting Antibody-drug Conjugate (ADC), for the treatment of...